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Background: Although G6PDd individuals are generally asymptomatic throughout their life, the clinical burden of
this genetic condition includes a range of haematological conditions, including acute haemolytic anaemia (AHA),
neonatal jaundice (NNJ) and chronic non-sphaerocytic anaemia (CNSA). In Latin America (LA), the huge knowledge
gap regarding G6PDd is related to the scarce understanding of the burden of clinical manifestation underlying
G6PDd carriage. The aim of this work was to study the clinical significance of G6PDd in LA and the Caribbean
region through a systematic review.
Methods: A systematic search of the published literature was undertaken in August 2013. Bibliographies of
manuscripts were also searched and additional references were identified. Only original research was included. All
study designs were included, as long as any clinical information was present. Studies were eligible for inclusion if
they reported clinical information from populations living in LA or Caribbean countries or about migrants from
these countries living in countries outside this continent.
Results: The Medline search generated 487 papers, and the LILACS search identified 140 papers. After applying the
inclusion criteria, 100 original papers with any clinical information on G6PDd in LA were retrieved. Additionally, 16
articles were included after reading the references from these papers. These 116 articles reported data from 18 LA
and Caribbean countries. The major clinical manifestations reported from LA countries were those related to AHA,
namely drug-induced haemolysis. Most of the published works regarding drug-induced haemolysis in LA referred
to haemolytic crises in P. vivax malaria patients during the course of the treatment with primaquine (PQ). Favism,
infection-induced haemolysis, NNJ and CNSA appear to play only a minor public health role in this continent.
Conclusion: Haemolysis in patients using PQ seems to be the major clinical manifestation of G6PDd in LA and
contributes to the morbidity of P. vivax infection in this continent, although the low number of reported cases,
which could be linked to under-reporting of complications. These results support the need for better strategies to
diagnose and manage G6PDd in malaria field conditions. Additionally, Malaria Control Programmes in LA should
not overlook this condition in their national guidelines.
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Glucose-6-phosphate dehydrogenase (G6PD) is an im-
portant enzyme that catalyses the first reaction in the
pentose-phosphate pathway. Within the erythrocyte,
G6PD is the sole source of enzymatic activity that
protects against the build-up of super-radicals and,
thus, oxidative stress [1,2]. G6PD deficiency (G6PDd) is
an X-linked, hereditary genetic defect caused by muta-
tions in the G6PD gene, resulting in protein variants
with different levels of enzymatic activity that are asso-
ciated with a wide range of biochemical and clinical
phenotypes [2]. G6PDd heterozygosity and hemizygos-
ity have been associated with approximately 50% pro-
tection against severe Plasmodium falciparum malaria
[3,4]. Therefore, the high prevalence rates of G6PDd in
many parts of the world can most likely be accounted
for by the selection pressure exerted by malaria. The
current estimated prevalence of G6PDd across malaria-
endemic countries is approximately 8%, which corresponds
to circa 350 million affected individuals in these countries.
The lowest prevalence is known to occur in the Americas,
while the highest prevalence is observed in tropical Africa,
Middle East and the Mediterranean basin [5].
Although G6PDd individuals are generally asymptom-
atic throughout their life, the clinical burden of this
genetic condition includes a range of haematological
conditions, including acute haemolytic anaemia (AHA),
neonatal jaundice (NNJ) and chronic non-sphaerocytic
anaemia (CNSA) [1,2]. Because AHA is the most com-
mon manifestation of G6PDd, it is critical to understand
how such episodes can be prevented. In G6PDd individ-
uals, these complications are usually triggered by the ad-
vent of specific infections or the intake of certain food
products, typically fava beans. As such, this inherited dis-
order is also known by the alternative name “favism”.
Complications can also be triggered by drugs, the prime
example of which is the anti-malarial primaquine (PQ).
The prevention of food-induced haemolytic crises, such
as in favism, should theoretically be fully preventable by
avoiding the triggering foods. In contrast, the preven-
tion of infection-induced haemolysis is obviously more
difficult. In most cases, the prevention of drug-induced
haemolysis is possible by choosing alternative drugs, but
this may be difficult when no alternatives are available.
This difficulty becomes particularly relevant when attempt-
ing to treat Plasmodium vivax infections, as radical cures,
including the specific treatment of the latent hepatic stages
that are mainly responsible for subsequent relapses after
the first clinical episode, require the use of PQ for 7 to
14 days. In some individuals, this treatment can lead to
life-threatening anaemia and acute renal failure [6]. In
these cases, administration of a lower dosage for a longer
time is the recommended approach, but only in those pa-
tients with mild-to-moderate enzymatic activity. In suchpatients, haemolysis will still occur, but under appropriate
surveillance, it will be of an acceptably mild degree [1]. Im-
portantly, the use of PQ in patients with a low enzymatic
activity is contraindicated. It is critical to understand that
the risk is variant-dependent and dose-dependent and cu-
mulative. PQ is also the only currently available drug that
is effective against P. falciparum stage V gametocytes. The
potentially hazardous effect of this drug in G6PDd indi-
viduals jeopardizes any population-wide effort to reduce
malaria transmission via drugs such as PQ due to the
impossibility of performing rapid population-wide screen-
ing for the deficiency and the hazards associated with the
blind administration of such drugs [7]. More recently, the
World Health Organization has recommended 0.25 mg/kg
of PQ in a single dose for patients with P. falciparum, as
this dose is efficacious as a gametocytocidal drug without
the risks of inducing haemolysis in G6PD patients [8].
A thorough understanding of the clinical burden related
to G6PDd could be of great value for understanding
whether particular drug regimens could be used safely at a
population level with or without prior knowledge of the
individuals’ G6PD status, or whether the development of
field-deployable and electricity-independent rapid diag-
nostic tests, resembling those that already exist for malaria
diagnosis, is indispensable. Some authors have recently
proposed maps of the G6PDd global distribution, in-
cluding LA countries, highlighting the small amount
of published works regarding this deficiency in this
continent [5,9]. Large swathes of the American malaria
endemic areas were predicted to have median G6PDd
frequencies ≤1% (40.8% land area), with G6PDd being
virtually absent from northern Mexico, Costa Rica, Peru,
Bolivia, and much of Argentina. The prevalence in-
creased towards coastal regions, peaking in Venezuela,
where the majority of the continent’s predictions of >5%
prevalence were located [5]. Only a limited repertoire of
variants was observed across LA countries, and surveys
indicated relatively low genetic heterogeneity, which was
predominated by the African variant [10]. Moreover, in
the Americas, the huge knowledge gap is related to the
scarce understanding of the burden of clinical manifest-
ation underlying G6PDd carriage. The aim of this work
was to study the clinical significance of G6PDd in LA
and the Caribbean region through the systematic review
of available published data.
Methods
Geographic coverage of the study
South America, Central America, Mexico and the
Caribbean area constitute a vast territory formed by 33
independent countries and 20 autonomous or semi-
autonomous territories. They cover a territorial area of
over 20 million km2, which included a population of ap-
proximately 580 million inhabitants in 2008. With regards
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and Uruguay, white people of European origin pre-
dominate. In others, such as Venezuela, Brazil, Paraguay,
Nicaragua and Colombia, white immigrants mixed notice-
ably with the Amerindians. Finally, in some countries, such
as Mexico, Guatemala, El Salvador, Honduras, Panama,
Peru, Bolivia and Ecuador, the Amerindians still constitute
a numerically important portion of the population. Add-
itionally, the continent has received multiple waves of
African immigrants, especially to the Caribbean area.
Systematic review
Potentially relevant papers in all languages were accessed
from Medline and LILACS to review their full texts. A
broad free text search using the combination of Medical
Subject Heading (MeSH) terms and keywords presented
in Table 1 was utilized.
Only original research of all study designs (clinical tri-
als, cohort studies, case–control studies, cross-sectional
studies, case series and case reports) was included, as
long as any clinical information was present. Additional
articles were obtained through citation tracking of re-
views, opinion articles and original papers. Studies were
eligible for inclusion if they reported clinical information
from populations living in LA or Caribbean countries or
about migrants from these countries living in countries
outside this continent. An individual was considered to
have G6PDd if they presented with any positive diagnos-
tic test, such as DNA analysis, enzyme activity assay,
NADPH fluorescent spot, brilliant cresyl blue, gel elec-
trophoresis, methylene reduction test or phenazine
methosulphate-3-(4,5-dimethylthiazal-2-yl)-2,5-diphenylte
trazolim bromide. In this study, clinical information refers
to G6PDd manifestations, such as AHA, NNJ and CNSA,
as well as G6PDd coexisting with other genetic disorders
and association of G6PDd with susceptibility or clinical
presentations of metabolic disorders or other infectious
diseases than malaria. In this study, a history of jaundice
or red cell transfusion after drug therapy was used as a
proxy for AHA. To identify relevant papers, the titles,
abstracts and the full texts of the studies were examined
by two independent reviewers. The data were directlyTable 1 Keywords and MESH headings used for literature sea
Database Search terms
Medline (favism OR glucosephosphate dehydrogenase OR glu
OR G-6-PD OR g-6-pd deficiency OR glucose-6-phosp
AND (Antilles OR Latin America OR South America OR
Barbuda OR Argentina OR Bahamas OR Barbados OR
Dominica OR Dominican Republic OR Ecuador OR El
Guyana OR Haiti OR Honduras OR Jamaica OR Martin
Paraguay OR Peru OR Puerto Rico OR Saint Kitts OR S
Tobago OR Uruguay OR Venezuela) [MeSH]
LILACS (favism OR glucosephosphate dehydrogenase OR glu
OR g-6-pd OR g-6-pd deficiency OR glucose-6-phospextracted from the full-length articles to structured table
and figures containing all the descriptive variables and
relevant outcomes.
Results
The Medline search generated 487 papers, and the
LILACS search generated 140 papers. After applying the
inclusion criteria to those papers, 100 original papers with
any clinical information on G6PDd in LA were retrieved.
Additionally, 16 articles were included after reading the
references of the 100 articles and reviews/ opinion articles
that were obtained from the Medline and LILACS searches
(Figure 1). These 116 articles reported data from 18 LA
countries.
Clinical manifestations of G6PDd in LA and Caribbean
populations
Acute haemolytic anaemia (AHA)
Additional file 1 and Figure 2 summarize the AHA find-
ings. Data on AHA were reported from 39 publications,
including 34 regarding drug-induced haemolysis, five
favism and three infection-induced haemolysis. Some in-
cluded publications presented two or more clinically
relevant G6PDd manifestations. A total of 107 character-
ized cases of AHA in LA were found. Out of these cases,
for 30 (28.0%), it was not possible to identify the trigger-
ing cause. Drug-induced haemolysis was responsible for
65 cases (60.7%), with PQ responsible for 47 (43.9%) and
other drugs/substances for 18 (16.8%) cases. Nine (8.4%)
cases of AHA were due to favism, and three (2.8%) cases
were attributed to infection-induced haemolysis.
Figure 2 shows that the AHA cases were mostly re-
ported in men (105/107; 98.1%). PQ-induced haemolysis,
favism and infection-induced haemolysis were reported
uniquely in males. Only 2 cases of haemolysis (one trig-
gered by naphthalene poisoning and one by salicylates),
were registered in females. Although AHA was observed
in all ages, most of the cases were reported in the young
population, with the median age ranging from 8 to
17 years for infection-induced haemolysis and PQ-induced
haemolysis, respectively. Case fatalities were reported only
among PQ-induced haemolysis cases, with a 4.3% rate.rches
cosephosphate dehydrogenase deficiency OR G6PD OR g6pd deficiency
hate dehydrogenase OR glucose-6-phosphate dehydrogenase deficiency)
Central America OR Caribbean OR Anguilla OR Antigua OR Aruba OR
Belize OR Bolivia OR Brazil OR Chile OR Colombia OR Costa Rica OR
Salvador OR Grenada OR Grenadines OR Guadeloupe OR Guatemala OR
ique OR Mexico OR Montserrat OR Nevis OR Nicaragua OR Panama OR
aint Lucia OR Saint Vincent OR Suriname OR Surinam OR Trinidad OR
cosephosphate dehydrogenase deficiency OR g6pd OR g6pd deficiency
hate dehydrogenase OR glucose-6-phosphate dehydrogenase deficiency)
Figure 1 Flow chart of inclusion of studies reporting clinical information on G6PD deficiency in Latin America and Caribbean countries.
Figure 2 Major findings on acute haemolytic anaemia in Latin America and the Caribbean countries.
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tify the ethnicity for only 24 (22.4%) subjects, being 8
(17.0%) presenting PQ-induced haemolysis, 8 with
haemolysis induced by other drugs/substances (44.4%),
6 with favism (66.7%) and 2 (66.7%) with infection-
induced haemolysis. PQ-induced haemolysis cases pre-
dominated among admixed individuals (7/8; 87.5%).
Haemolysis induced by other drugs/substances (6/8; 75%)
and infection-induced haemolysis (2/2;100%) predomi-
nated among black individuals. Favism was recorded in
white individuals only (6/6; 100%).
Figure 3 shows the geographic distribution of the
AHA cases in which it was possible to identify the trig-
gering haemolytic cause. The highest number of cases
was reported in Brazil (26; 33.8%), followed by Cuba
(19 cases; 26.7%) and Chile (18 cases; 23.4%). Primaquine-
induced haemolysis was reported in Brazil (23 cases;
48.9%), Cuba (18 cases; 38.3%), El Salvador (three cases;
6.4%), Puerto Rico (two cases; 4.3%), and Trinidad and
Tobago (one case; 2.1%).
Drug-induced haemolysis
Some cross-sectional studies with a recall approach
showed an absence of signs of haemolysis among the
G6PD deficient population [11-14]. One study showedFigure 3 Geographic distribution of the acute haemolytic anaemia ca
Caribbean countries. The circles are proportional to the number of casesthat patients who received blood donated by G6PDd in-
dividuals did not develop haemolysis, even though some
were using drugs that could potentially trigger this compli-
cation [15]. Some studies showed a higher frequency of
previous history of jaundice in G6PDd in relation to non-
G6PDd individuals [16], or a higher frequency of G6PDd
in patients with history of acute haemolytic crises in com-
parison with the general population [17]. However, haem-
olysis caused by G6PDd was generally mild [16,18,19].
Reports of occasional moderate haemolytic anaemia
were reported in Brazil [20], Costa Rica [21] and Mexico
[18,22,23], with poor clinical descriptions and no identi-
fication of the stressor. No complication was reported in
patients using the single dose of PQ (0.75 mg/kg) for
P. falciparum gametocytes. In Mexico [24], Ecuador
[25] and Chile [26], the frequency of G6PDd in patients
with haemolytic anaemia was 30.3, 8.6 and 39.5%, respect-
ively, but the authors did not detail the haemolysis-
triggering causes for all patients. Haemolytic episodes in
G6PD deficient subjects related to naphthalene intoxica-
tion, use of salicylates, transfusion of G6PDd blood into
recipients with leprosy under sulpha drug therapy and ex-
cessive intake of rum or wine were reported in Curaçao
[27]. In LA countries, there were reports of drug-induced
haemolytic episodes triggered by nalidixic acid [28],ses, according to triggering causes, in Latin American and
at the site.
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[26,30,31], sulphazoxazole plus nitrofurantoin [32] and
acetaminosalol [26]. In Brazil, G6PDd did not seem to be
associated with a higher risk of haemolysis in patients who
were being treated with sulphone [33], ketoconazole [34],
or who were under spinal anaesthesia with bupivacaine or
general intravenous anaesthesia with propofol [35]. In Saint
Lucia, G6PD-deficient children infected with S. mansoni
were given a single intramuscular dose of hycanthone, but
their subsequent serial haematocrit and reticulocyte counts
showed no evidence of haemolysis [36].
In 1970, three patients from El Salvador who pre-
sented with PQ-induced haemolysis were confirmed as
G6PD deficient, and one of these patients required an
exchange transfusion [29]. Two cases of PQ-induced
haemolysis were reported from Puerto Rico [32]. Haem-
olysis appeared in 87.5% of 16 G6PD-deficient patients
from Cuba. This effect occurred mainly on the fifth day
of treatment, after the administration of 105 mg of PQ
[37]. In Trinidad, the management of two imported
cerebral malaria cases was complicated by their G6PD-
deficient status, with the occurrence of blackwater fever,
cerebral manifestations, renal impairment, hypergly-
caemia and thrombocytopaenia [38]. In Cuba, there were
reports of haemolysis in six of eight (87.5%) G6PDd pa-
tients treated with PQ, three of whom could not finish
the treatment [39]. Treatment discontinuation was also
described in cases from Brazil, where three G6PDd
patients with vivax malaria in a chloroquine plus PQ
regimen presented with AHA [40]. In a similar regimen,
18 G6PD-deficient patients presented with AHA that re-
quired red blood cell transfusions and finally developed
acute renal failure [41]. In the Brazilian Amazon, G6PDd
was associated with a considerably higher risk of malaria-
related transfusions likely triggered by the treatment for
malarial infection [42,43]. In Manaus, an autopsy series
of deceased patients with confirmed P. vivax infection
could only attribute the cause of death to PQ-induced
haemolysis, demonstrating the lethal potential of this
condition [44].
The use of chloroquine alone did not trigger haemolysis
in 8 G6PD-deficient subjects [45].
Favism
The search identified five publications from Chile that
reported a total of nine cases of favism in LA [26,46-49].
All cases occurred in males, and most were in children.
In three cases, blood transfusions were needed, and one
individual evolved to acute renal failure. There was no
record of case fatalities.
Infection-induced haemolysis
In Cuba, recurrent viral and bacterial infections were in-
dicated as possible causes of haemolysis in an 8-year-oldboy [19]. In Curaçao, one case of haemolytic anaemia in
a G6PD-deficient subject was related to a febrile non-
defined viral infection [27]. In El Salvador, one episode
of haemolysis was reported in a patient with an infection
without defined aetiology, but the stressor was not char-
acterized because the subject was taking aspirin [29]. A
clear aetiological trigger could not be confirmed in any
of these cases.
Neonatal jaundice (NNJ)
Neonatal jaundice was reported in 30 original articles.
The frequency of NNJ in G6PD-deficient new-borns
ranged from 38.5 to 100% [50-56]. However, excluding
other causes, the aetiology of jaundice was attributed
to G6PDd in 5 [57] to 15% [58] of the new-borns.
On the other hand, G6PDd was detected in 3.4% of male
new-borns with NNJ in the absence of foetal-maternal in-
compatibility in Costa Rica [59] and in 69.6% of a group of
neonates who had unexplained moderate to severe jaun-
dice [60]. Four studies reported no severe complications in
G6PD-deficient new-borns with NNJ [53,54,56,59], while
three works described the need for exchange transfusions
[50,51,55], three described the occurrence of kernicterus
[51,60,61], and two described fatal outcomes [29,60].
Some cross-sectional studies have demonstrated that
NNJ cannot be solely attributed to G6PDd [62] or a lack
of association between G6PDd and NNJ [24,63-67]. In
Trinidad, a similarity between the frequencies of enzyme
defects in normal children and those with cerebral palsy
suggested that neonatal jaundice associated with G6PDd
may be a factor of little significance in the development
of kernicterus and subsequent cerebral palsy, even in a
community with a high prevalence of this enzyme defi-
ciency [68]. In a prospective study from Brazil, G6PDd
did not appear as a risk factor for moderate hyperbiliru-
binaemia [69], and in a case–control study in the same
country, G6PDd was not found to be related to severe
hyperbilirubinaemia [70]. Other reports have found contra-
dictory results about the relationship between G6PDd and
NNJ in LA, suggesting that there was a positive association
between G6PDd and NNJ [71-77]. In a work from Mexico,
the prevalence of NNJ was only linked to G6PDd in male
babies [52].
Chronic non-sphaerocytic anaemia (CNSA)
Data concerning the association between G6PDd and
anaemia, including chronic non-sphaerocytic anaemia,
were presented in 18 articles. Only 8 defined cases of
CNSA were recorded from Latin America, with 2 from
Brazil [78,79], 2 from Chile [80] and 1 each from Cuba
[81], Costa Rica [82], Mexico [24] and Puerto Rico [32].
However, in general, these publications had poor clinical
descriptions, as they were primarily aimed at characteris-
ing the enzyme. Of these cases, those from Chile had
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aemia with the need for blood transfusions, reticulocyto-
sis, jaundice and splenomegaly [80]. Cholelithiasis is a
complication that can follow CNSA, but in Brazil, there
was no association between the need for cholecystec-
tomy and G6PDd [83]. In a study from Brazil [84] and
in another from Colombia [85], G6PD-deficient subjects
showed a lower level of haemoglobin than the normal
individuals.
Most of the published reports describing haemato-
logical parameters in LA, which covered several distinct
geographical areas, showed similar haematimetric indexes
in G6PDd individuals and non-deficient ones [86-92]. In
Brazil, a low incidence of anaemia conferred no important
haematological changes in individuals in which G6PDd
was found [93].
Coexistence of G6PDd with other genetic disorders
The coexistence of G6PDd with other genetic disor-
ders was reported in 14 articles. In Argentina, beta-
thalassemia was detected in 4.8% of the G6PD-deficient
subjects [94], and the concurrence of haemoglobin S and
congenital sphaerocytosis with G6PDd was detected in 4
and 2% of the subjects, respectively [50]. In Brazil, haemo-
globin S was detected in 11.1% of the G6PD-deficient indi-
viduals [95]. In Costa Rica, the frequency of G6PDd
among male HbAS carriers ranged from 2.3 [96] to 15%
[97]. However, controlled studies have shown that G6PDd
is independent from the occurrence of abnormal haemo-
globin [27,98-100], HbS or HbC [101] sickle cell trait
[102] and sickle cell disease [103]. In Jamaica, difference in
G6PD status did not affect the total haemoglobin concen-
tration, reticulocyte count, unconjugated serum bilirubin,
Hb F concentration, plasma haemoglobin concentration
and frequencies of clinical severity and of leg ulceration in
patients with sickle cell disease [104]. In Brazil, G6PDd
was absent in nine children with clinical diagnosis of gly-
cogenoses [105].
G6PDd and malaria susceptibility
An association between G6PDd and malaria susceptibil-
ity was reported in 8 articles. In a traditionally malaria-
endemic area of South-eastern Brazil, the frequency of
G6PDd and average G6PD activity was similar between
the groups with and without a history of malaria [106].
Plasmodium falciparum infections were recorded at the
same proportion in G6PDd and normal individuals in
the Southern Brazilian Amazon [107]. In Brazil, an ab-
sence of association between G6PD phenotypes and the
number of previous episodes of malaria in men was re-
ported [108]. However, in Ecuador, G6PDd prevalence
was higher in provinces that were non-endemic for
malaria, compared to endemic provinces, suggesting an
ecological association between G6PDd and some degreeof protection against P. falciparum [109]. Colombian in-
dividuals with a complete G6PD deficiency had a lower
density of P. falciparum parasitaemia than persons with-
out this condition [110]. In Colombia, the mean G6PD
activity was lower, and G6PDd was more prevalent
among men without P. vivax malaria than in those pre-
senting with the disease [111]. In the Brazilian Amazon,
where P. vivax predominates, G6PDd individuals were
less likely to report the occurrence of malaria episodes
after adjusting for age [42,43]. In the same area, the
protective effect was related to the enzymatic activity,
with carriers of the African variant presenting an 88%
reduction and carriers of the Mediterranean variant
presenting a 99% lower risk compared to non-deficient
individuals [43].
G6PDd and metabolic disorders
The presence of metabolic disorders in G6PDd patients
was investigated in three articles. Significantly lower
insulin levels were observed for G6PDd Brazilian men
compared to the controls in both the intravenous and
oral tolerance tests [112]. In Mexico, two diabetic
G6PDd individuals did not show cataracts, whereas
cataracts were identified in six other diabetic patients
[113]. In Brazil, the mean cortisol levels observed in
the first hour after ACTH stimulation in the G6PD-
deficient patients were significantly lower than in the
control group [114].
Other findings
Other findings were mentioned in 10 original articles. A
significant increase in methaemoglobinaemia was ob-
served following oral therapy with PQ in patients
with P. vivax presenting G6PDd [115,116]. Additionally,
in Colombia, an association between haemolysis and phys-
ical exercise was observed in individuals with reduced
G6PD activity [117]. In Brazil, G6PDd was suggested to
contribute to haemolysis in patients with the viscerocuta-
neous form of loxoscelism, a condition produced by the
bite of the recluse spiders of genus Loxosceles [118]. In
Brazil, there have been reports of recurrent infections in
children diagnosed with G6PDd [119,120]. In contrast, in-
creased rates of urinary tract infections and neonatal jaun-
dice were not substantiated among pregnant women from
Puerto Rico, Dominican Republic, Mexico and other
Caribbean areas living in the United States. However, the
same authors reported increased rates of abortions, low-
birth-weight infants and puerperal drops in red cell vol-
umes in this population [64]. Transfusions of G6PDd
blood that has been typed as the African variant seems to
be safe, as a study carried out in Brazil had no reports of
major haemolysis in recipients [121]. In Brazil, there was a
lack of association between G6PDd and S. mansoni [122]
and leprosy susceptibility [123].
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Mapping studies have demonstrated that P. vivax is
more widely distributed than P. falciparum and that this
species is a potential cause of morbidity and mortality
amongst the 2.85 billion people living at risk of infection,
most of whom live in Central and South East Asia and
LA [124]. In LA and the Caribbean, most of the coun-
tries remain endemic for malaria. Only Chile, Uruguay,
Cuba, Bahamas, Jamaica and other small countries in
the Caribbean are now considered malaria-free. Mexico,
Haiti, Costa Rica, El Salvador, Panama, Argentina and
Paraguay are classified as ‘malaria-eliminating’ countries.
The others are still in phases of control [125]. The pre-
dominance of vivax malaria in these countries is espe-
cially relevant because the radical cure of P. vivax
infections requires the use of PQ, which can lead to
acute intravascular haemolysis in G6PDd individuals,
resulting in severe anaemia and acute renal failure [6].
The public health consequences of this condition de-
serve special attention due to the impossibility of using
PQ in regions where there is a high prevalence of this
deficiency, further hampering transmission control ef-
forts for this parasite species [7]. Despite the clinical and
epidemiological significance of the interaction between
G6PDd and malaria, the extent of its clinical consequences
has not been properly measured in LA populations. In
countries such as Brazil, where PQ is systematically pre-
scribed at a dose of 0.5 mg/kg/day for 7 days with chloro-
quine to all patients with microscopic confirmation of
vivax malaria, the cumulative risk of adverse events in
G6PDd patients could be even more relevant.
The most commonly reported clinical manifestations
reported from LA countries were those related to AHA,
namely drug-induced haemolysis. In patients with haemo-
lytic anaemia, the reported frequency of G6PDd could be
higher than 30% [24,26,126]. Favism and infection-induced
haemolysis appear to play only a minor public health role
in this continent. In general, in population-based studies
carried out in regions where malaria is not endemic, indi-
viduals did not show a great risk of developing G6PDd-
related haemolysis in their lifetimes [11-14,16,18,19],
despite the establishment of an association between jaun-
dice or history of haemolysis with G6PDd by some
authors [16,17]. Another important finding in this context
is the difficulty in linking G6PDd-related haemolysis with a
specific stressor drug [20,22,23,25,26,126,127]. As reported,
only a few sporadic haemolytic episodes were triggered by
nalidixic acid, chloramphenicol, aspirin, salicylates,
sulfadiazine, sulphazoxazole and nitrofurantoin and by
naphthalene poisoning. These drugs or their metabolites
are already known to be haemolysis triggers, most likely
due to the production of free radicals, which in turn
oxidize glutathione (GSH) and eventually lead to cell
damage [128].Most of the published works regarding drug-induced
haemolysis in LA referred to haemolytic crises in pa-
tients diagnosed with P. vivax malaria during the course
of the treatment with PQ. Reports of the need for red
cell transfusions were common in these cases. In this
continent, complications such as severe anaemia and
renal failure also seem to be common and are of public
health concern. Likewise, lethality was reported in the
Brazilian Amazon, highlighting the impact on the local
public health systems. Most strikingly, the results of two
studies showed that the frequency of haemolysis in
G6PDd patients was almost 90% [37,39]. Specifically, the
most feared complication of PQ administration is the
precipitation of haemolysis in G6PDd individuals. Other
major PQ side effects that were identified in this review
included methaemoglobinaemia, which again, mostly oc-
curred among G6PDd patients. In this context, discontinu-
ation of PQ treatment was observed in some countries,
strongly suggesting that G6PDd in LA is hampering the
transmission control efforts for P. vivax.
American countries contribute to 4.5% of the G6PDd
male population from malaria endemic countries, corre-
sponding to an estimated 10 million males, according to
population data from 2010 [5]. Based on this estimation
of G6PDd males living at risk of vivax malaria and con-
sequently, of PQ-induced haemolysis, the number of AHA
cases most likely is deeply underestimated, considering the
literature data presented here. Firstly, this bias is likely re-
lated to a failure to recognize or properly diagnose AHA
episodes among the malaria-affected population. In LA,
malaria diagnosis and treatment are mostly made by tech-
nicians and only a few cases, especially complicated cases,
are referred to tertiary-care centres. Accordingly, there is a
lack of systematic diagnosis and surveillance of PQ-
induced haemolysis in these countries, possibly leading to
a significant proportion of under diagnosed cases. Second-
arily, this lack of attention could lead to publication bias,
as not many research groups are working in units linked to
the tertiary health services located in malaria endemic
areas. Therefore, published studies may not be truly repre-
sentative of all of the information about G6PDd in LA,
thus introducing a limitation to this systematic review.
This review points to the need for systematic testing
of G6PDd in LA malaria endemic countries. Only with
this result would it be possible to appropriately guide
treatment, adjusting the PQ dosage or even contraindi-
cating the drug, depending on the enzymatic activity of
G6PD. The exposed population is extremely large in many
endemic areas, and testing for G6PD status in all individ-
uals would be a costly exercise, the cost-effectiveness of
which remains to be evaluated. Furthermore, only a small
number of investigations estimating G6PDd prevalence
and the relative frequencies of the different genetic variants
were carried out in LA malaria-endemic areas. Studies
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prevalence of 4%, with the African and Mediterranean
variants predominating [43]. This review found that in
publications from LA, PQ-induced haemolysis was only
reported among males. This observation is in agreement
with previous reports that clinically relevant G6PDd is
much more common in males than in females because
of the genetic nature of this condition. This result is of
great significance for public health programmes because
hemizygous females carrying G6PDd variants seem to be
at reduced risk of PQ-induced haemolysis. The distinct-
ive regional-specific character of the G6PDd clinical pic-
ture may help in the development of more targeted
diagnostic approaches and PQ therapeutic strategies. In
this regard, only testing the male population for G6PDd
may be a more efficient and cheaper measure for mini-
mising the risk of clinically relevant haemolysis after PQ
administration in LA malaria-endemic areas.
A sound analysis on the role of the ethnicity in the
geospatial distribution of G6PDd-related events was
greatly impaired by the lack of information on ethnicity
background for research subjects. It is known that global
prevalence of G6PDd, and probably of its clinical mani-
festations, is geographically correlated with areas inhab-
ited by populations historically exposed to endemic
malaria, including Africa, Middle East, Mediterranean
Europe and South-East Asia [5]. In this work, PQ-induced
haemolysis predominated among admixed individuals,
reflecting probably the ethnic composition of population
living in P. vivax malaria endemic areas, and consequently
the areas where PQ is prescribed, namely the Amazon.
Favism was recorded in white individuals, in agreement
with the literature that points that this is a condition typ-
ical of males of Mediterranean descent.
As previously demonstrated, the combination of
G6PDd with the sickle cell trait was no more frequent
than that expected by chance [129]. Several studies have
shown that there are no significant differences in a var-
iety of clinical and haematologic parameters between
two otherwise comparable groups of patients with sickle
cell anaemia, those with and without G6PD deficiency
[130,131]. However, it must be borne in mind that acute
intravascular haemolysis superimposed with chronic se-
vere extravascular haemolysis is an added risk within
this association. The combination of G6PDd with the β-
thalassaemia trait has been found to cause a significant
increase in mean corpuscular volume [132], although it
remains below the normal range.
In LA, there are results suggesting that G6PDd preva-
lence could be a marker of the selective pressure exerted
by malaria. The geographic distribution of G6PDd suggests
that some polymorphisms confer resistance to falciparum
malaria [5]. This phenomenon has been investigated
mainly for the African variant, which has been shown toconfer protection against lethal falciparum malaria [4]. In
P. falciparum infections, it has been demonstrated that the
shorter half-life and rapid clearance of red cells of G6PDd
individuals make them less susceptible to malarial attacks
from these parasites [133], and it is likely that a similar
pathophysiological mechanism could occur in P. vivax-in-
fected cells. However, there is a need to further explore
and comprehend the mechanisms by which individuals
with G6PDd are rendered less susceptible to infection.
P. vivax preferentially invades reticulocytes, but P. falcip-
arum can invade erythrocytes of all ages. This erythro-
cyte invasion is a significant phenomenon because G6PD
activity is markedly reduced in older erythrocytes. Thus,
red cells infected with P. vivax are most likely less vulner-
able to the oxidant stress produced by the parasite. The
precise mechanism by which G6PDd promotes reduced
susceptibility to vivax malaria remains to be established.
Concluding remarks
Currently, the only drug available for the elimination of
P. vivax hypnozoites is PQ. Tafenoquine is another drug
of the same group that is being evaluated in clinical trials
[134]. This unique therapeutic class of drugs is extremely
useful in the control and eventually, in the elimination of
malaria. However, in the absence of a rapid diagnostic test
to detect G6PDd, the potential for toxicity in individuals
with this condition limits the safe and effective use of such
drugs because of the hazardous and even life-threatening
side effects. Indeed, this work shows that haemolysis in pa-
tients using PQ is not infrequent and contributes to the
morbidity of infection caused by P. vivax in LA, thus
representing the major clinical complication of G6PDd in
this continent. PQ-induced haemolysis was only reported
in males, thus indicating that testing only this population
for G6PDd may be a more efficient and cheaper measure
for minimising the risk of clinically relevant haemolysis
after PQ administration in LA malaria endemic areas.
It is likely that the real impact of G6PDd in terms of
malaria-related complications has been heavily underes-
timated, and further research should be devoted to clari-
fying the real burden that these complications impose
on the health systems. Finally, this study highlights the
need to improve current strategies for diagnosing and
managing G6PDd in malaria field conditions. Malaria con-
trol programmes in LA need to take this condition into
serious account in their national guidelines if measures
such as massive PQ administration are considered as part
of regional malaria elimination agendas.Additional file
Additional file 1: Summary of the findings organized by the type of
stressor triggering haemolysis in G6PDd patients.
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